

A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN GERIATRIC PSYCHIATRY

The American Board of Psychiatry and Neurology, Inc. (ABPN) is a not-for-profit corporation dedicated to serving the public interest and the professions of psychiatry and neurology by promoting excellence in practice through certification and continuing certification processes.

The ABPN designs and develops the geriatric psychiatry certification examination to assess the knowledge and reasoning skills needed to provide high quality patient care in the broad domain of the subspecialty. It utilizes two-dimensional content specifications. Within the two-dimensional format, one dimension is comprised of disorders and topics while the other is comprised of competencies and mechanisms that cut across the various disorders of the first dimension. By design, the two dimensions are interrelated and not independent of each other. All of the questions on the examination will fall into one of the disorders/topics and will be aligned with a competency/mechanism. For example, an item on substance use could focus on treatment, or it could focus on systems-based practice.

Candidates should use the detailed content specifications as a guide to prepare for a certification examination. Scores for these examinations will be reported in a standardized format rather than the previous percent correct format.

For more information, please contact us at questions@abpn.org or visit our website at <a href="ma



A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN GERIATRIC PSYCHIATRY Content Blueprint

Number of	Number of questions: 220	
	Dimension 1	
	Psychiatric Disorders and Topics	
		T
01.	Developmental processes and development through the life cycle	3-5%
02.	Neurodevelopmental disorders	1-2%
03.	Substance-related and addictive disorders	7-9%
04.	Schizophrenia spectrum and other psychotic disorders	5-7%
05.	Depressive disorders	9-11%
06.	Bipolar and related disorders	5-7%
07.	Anxiety disorders	7-9%
08.	Obsessive-compulsive and related disorders	1-3%
09.	Trauma- and stressor-related disorders	3-5%
10.	Dissociative disorders	1-2%
11.	Somatic symptom and related disorders	1-3%
12.	Eating disorders	1-2%
13.	Sleep-wake disorders	2-4%
14.	Sexual dysfunctions	1-3%
15.	Gender dysphoria	1-2%
16.	Disruptive, impulse-control, and conduct disorders	1-2%
17.	Personality disorders	1-3%
18.	Paraphilic disorders	1-2%
19.	Other conditions that may be a focus of clinical attention	9-11%
20.	Neurocognitive disorders	14-16%
21.	Neurologic disorders	4-6%
22.	Forensic psychiatry	1-3%
23.	Dimension 2 topics without a corresponding Dimension 1 topic	4-6%



A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN GERIATRIC PSYCHIATRY Content Blueprint

Number of questions: 220		
	Dimension 2	
	Physician Competencies and Mechanisms	
A.	Neuroscience and mechanisms of disease	7-9%
В.	Behavioral/social sciences and psychosocial mechanisms of	4-6%
	diseases	
C.	Clinical aspects of psychiatric and neuropsychiatric disorders	24-26%
D.	Diagnostic procedures	11-13%
E.	Treatment	32-34%
F.	Interpersonal and communication skills	1-3%
G.	Professionalism, ethics, and the law	2-4%
H.	Practice-based learning and improvement	1-3%
I.	Systems-based practice	9-11%



A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN GERIATRIC PSYCHIATRY Content Outline

Dimension 1	
Psychiatric Disorders and Topics	
01. Developmental processes and development through the life cycle (psychiatry and	
neurology)	
a. Late life	
i. Personality adaptation and other developmental processes	
ii. Psychosocial influences	
a. Life course – developmental and transitional events (retirement, death of a spouse	(ة
iii. Acquisition and loss of specific capacities	
a. Systemic, anatomic, and physiologic changes	
b. Psychological changes	
c. Other	
iv. Other	
02. Neurodevelopmental disorders	
a. Intellectual developmental disorder (intellectual disability)	
b. Autistic spectrum disorder	
c. Attention deficit/hyperactivity disorder	
d. Specific learning disorder	
e. Tourette disorder	
f. Persistent (chronic) motor or vocal tic disorder	
03. Substance-related and addictive disorders	
a. Alcohol-related disorders	
b. Caffeine-related disorders	
c. Cannabis-related disorders	
d. Other hallucinogen-related disorders	
e. Inhalant-related disorders	
f. Opioid-related disorders	
g. Sedative-, hypnotic-, or anxiolytic-related disorders	
h. Stimulant-related disorders	
i. Tobacco-related disorders	
j. Other (or unknown) substance-related disorders	



k.	Cambling disarder
l.	Gambling disorder Phencyclidine-related disorders
	nizophrenia spectrum and other psychotic disorders
a.	Delusional disorder
b.	
	Brief psychotic disorder Schizophroniform disorder
c. d.	Schizophreniform disorder Schizophrenia
e.	Schizoaffective disorder
f.	
	Substance/medication-induced psychotic disorder Description disorder due to another medical condition
g. h.	Psychotic disorder due to another medical condition Catatonia
i.	Catatonic disorder due to another medical condition
J.	Unspecified catatonia
k.	Other specified schizophrenia spectrum and other psychotic disorder
OF Do	Unspecified schizophrenia spectrum and other psychotic disorder
	pressive disorders
а. b.	Major depressive disorder
	Persistent depressive disorder (dysthymia)
c. d.	Premenstrual dysphoric disorder Substance/medication induced depressive disorder
	Substance/medication-induced depressive disorder Depressive disorder due to another medical condition
e. f.	·
	Other specified depressive disorder
g. h.	Unspecified depressive disorder Unspecified mood disorder
-	polar and related disorders
а.	Bipolar I disorder
	Bipolar II disorder
	Cyclothymic disorder
d.	Substance/medication-induced bipolar and related disorders
	Bipolar and related disorder due to another medical condition
e. f.	Other specified bipolar and related disorder
	Unspecified bipolar and related disorder
9. 07 An	xiety disorders
a.	Separation anxiety disorder
b.	Selective mutism
D.	Selective mutism



	Specific phobia
	Social anxiety disorder
	Panic disorder
f. <i>F</i>	Agoraphobia
g. (Generalized anxiety disorder
h. 9	Substance/medication-induced anxiety disorder
i. <i>i</i>	Anxiety disorder due to another medical condition
j. (Other specified anxiety disorder
k. l	Jnspecified anxiety disorder
08. Obs	essive-compulsive and related disorders
a. (Obsessive-compulsive disorder
b. I	Body dysmorphic disorder
c. I	Hoarding disorder
d. ⁻	Trichotillomania (hair-pulling disorder)
e. I	Excoriation (skin-picking) disorder
f. 9	Substance/medication-induced obsessive-compulsive and related disorder
g. (Obsessive-compulsive and related disorder due to another medical condition
h. (Other specified obsessive-compulsive and related disorder
i. l	Unspecified obsessive-compulsive and related disorder
09. Trau	ıma- and stressor-related disorders
a. I	Posttraumatic stress disorder
b. <i>A</i>	Acute stress disorder
c. <i>A</i>	Adjustment disorders
d. F	Prolonged grief disorder
e. (Other specified trauma- and stressor-related disorder
f. l	Jnspecified trauma- and stressor-related disorder
10. Diss	ociative disorders
a. [Dissociative identity disorder
b. 1	Dissociative amnesia
c. I	Depersonalization/derealization disorder
d. (Other specified dissociative disorder
e. l	Jnspecified dissociative disorder
11. Som	atic symptom and related disorders
a. S	Somatic symptom disorder
b. 1	llness anxiety disorder



C.	Functional neurological symptom disorder (conversion disorder)
d.	Psychological factors affecting other medical conditions
e.	Factitious disorder
f.	Other specified somatic symptom and related disorder
g.	Unspecified somatic symptom and related disorder
12. Fee	eding and eating disorders
a.	Pica
b.	Rumination disorder
c.	Avoidant/restrictive food intake disorder
d.	Anorexia nervosa
e.	Bulimia nervosa
f.	Binge-eating disorder
g.	Other specified feeding or eating disorder
h.	Unspecified feeding or eating disorder
13. Sle	ep-wake disorders
a.	Insomnia disorder
b.	Hypersomnolence disorder
c.	Narcolepsy
d.	Obstructive sleep apnea hypopnea
e.	Central sleep apnea
f.	Sleep-related hypoventilation
g.	Circadian rhythm sleep-wake disorders
h.	Non-REM sleep arousal disorders
i.	REM sleep behavior disorder
j.	Restless legs syndrome
k.	Substance/medication-induced sleep disorder
l.	Other specified insomnia disorder
m.	Unspecified insomnia disorder
n.	Other specified hypersomnolence disorder
0.	Unspecified hypersomnolence disorder
p.	Other specified sleep-wake disorder
q.	Unspecified sleep-wake disorder
14. Se	rual dysfunctions
a.	Delayed ejaculation
b.	Erectile disorder



•	
c.	Female orgasmic disorder
d.	Female sexual interest/arousal disorder
e.	Genito-pelvic pain/penetration disorder
f.	Male hypoactive sexual desire disorder
g.	Premature (early) ejaculation
h.	Substance/medication-induced sexual dysfunction
i.	Other specified sexual dysfunction
j.	Unspecified sexual dysfunction
15. Ger	nder dysphoria
a.	Other specified gender dysphoria
b.	Unspecified gender dysphoria
16. Dis	ruptive, impulse-control, and conduct disorders
a.	Pyromania
b.	Kleptomania
C.	Other specified disruptive, impulse-control, and conduct disorder
d.	Unspecified disruptive, impulse-control and conduct disorder
17. Per	sonality disorders
a.	Paranoid personality disorder
b.	Schizoid personality disorder
c.	Schizotypal personality disorder
d.	Antisocial personality disorder
e.	Borderline personality disorder
f.	Histrionic personality disorder
g.	Narcissistic personality disorder
	Avoidant personality disorder
i.	Dependent personality disorder
j.	Obsessive-compulsive personality disorder
k.	Personality change due to another medical condition
l.	Other specified personality disorder
m.	Unspecified personality disorder
n.	General personality disorder
18. Par	aphilic disorders
a.	Voyeuristic disorder
b.	Exhibitionistic disorder
c.	Frotteuristic disorder



d. Sexual masochism disorder	
e. Sexual sadism disorder	
f. Pedophilic disorder	
g. Fetishistic disorder	
h. Transvestic disorder	
i. Other specified paraphilic disorder	
j. Unspecified paraphilic disorder	
19. Other conditions that may be a focus of clinical attention	
20. Neurocognitive disorders	
a. Delirium	
b. Other specified delirium	
c. Unspecified delirium	
d. Major or mild neurocognitive disorder due to Alzheimer disease	
e. Major or mild frontotemporal neurocognitive disorder	
f. Major or mild neurocognitive disorder with Lewy bodies	
g. Major or mild vascular neurocognitive disorder	
h. Major or mild neurocognitive disorder due to traumatic brain injury	
i. Substance/medication-induced major or mild neurocognitive disorder	
j. Major or mild neurocognitive disorder due to HIV infection	
k. Major or mild neurocognitive disorder due to prion disease	
l. Major or mild neurocognitive disorder due to Parkinson disease	
m. Major or mild neurocognitive disorder due to Huntington disease	
n. Major or mild neurocognitive disorder due to another medical condition	
o. Major or mild neurocognitive disorder due to multiple etiologies	
p. Unspecified neurocognitive disorder	
21. Neurologic disorders	
a. Infections of the nervous system	
b. Vascular diseases	
c. Disorders of cerebrospinal and brain fluids	
d. Neuro-oncology	
e. Trauma	
f. Cranial nerve disorders	
g. Peripheral neuropathies	
h. Ataxias	
i. Headache	



A Member Board of the American Board of Medical Specialties (ABMS)

j.	Movement disorders
k.	Spinal cord diseases
l.	Neuromuscular junction disorders
m.	Myopathies
n.	Demyelinating diseases
0.	Epilepsy and episodic disorders
p.	Neurologic complications of systemic diseases
q.	Neurotoxicology
r.	Pain syndromes
S.	Other
22. Fo ı	rensic psychiatry
a.	Civil
b.	Children/families
23. Dir	nension 2 topics without a corresponding Dimension 1 topic



	Dimension 2
	Physician Competencies and Mechanisms
A.	Neuroscience and mechanisms of disease
	I. Neuroanatomy
	II. Cellular and molecular neurobiology
	III. Neuropathology
	IV. Genetics
	V. Neurochemistry
	VI. Neurophysiology
	VII. Chronobiology (e.g., biological rhythms, sleep)
	VIII. Neuroendocrinology and neuroimmunology
	IX. Other
В.	Behavioral/social sciences and psychosocial mechanisms of diseases
	I. Psychology
	i. Neuropsychology, cognitive psychology
	ii. Social psychology
	iii. Psychoanalytic and psychodynamic psychology
	iv. Other
	II. Sociology
	III. Anthropology, culture, ethnicity, race, and spirituality
	IV. Biostatistics
	V. Other
	VI. Normal development
C.	
	I. Epidemiology
	II. Factors affecting psychiatric and neuropsychiatric disorders (predisposing, protective, and
	perpetuating factors, precipitants)
	III. Clinical presentation, symptoms, and signs
	IV. Comorbidity
	V. Differential diagnosis
	VI. Prognosis and course of illness
D.	
	I. General physical and neurological examination
	II. Psychiatric interview and mental status examination
	III. Psychological testing



A Member Board of the American Board of Medical Specialties (ABMS)

IV. Neuropsychological testing V. Diagnostic assessments and rating scales VI. Laboratory testing VIII. Neuroimaging VIII. EEG IX. Sleep Studies X. Neurophysiologic testing XI. Other E. Treatment I. General treatment planning and decision making II. General principles of psychopharmacology and neuropharmacology i. Pharmacokinetics/pharmacodynamics ii. Drug interactions iii. Age, gender, and ethnicity issues iv. Genomics III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI) iv. Selective norepinephrine reuptake inhibitors (NRI)	
VII. Laboratory testing VIII. Neuroimaging VIII. EEG IX. Sleep Studies X. Neurophysiologic testing XI. Other E. Treatment I. General treatment planning and decision making II. General principles of psychopharmacology and neuropharmacology i. Pharmacokinetics/pharmacodynamics ii. Drug interactions iii. Age, gender, and ethnicity issues iv. Genomics III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
VIII. Neuroimaging VIII. EEG IX. Sleep Studies X. Neurophysiologic testing XI. Other E. Treatment I. General treatment planning and decision making III. General principles of psychopharmacology and neuropharmacology i. Pharmacokinetics/pharmacodynamics ii. Drug interactions iii. Age, gender, and ethnicity issues iv. Genomics III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
VIII. EEG IX. Sleep Studies X. Neurophysiologic testing XI. Other E. Treatment I. General treatment planning and decision making II. General principles of psychopharmacology and neuropharmacology i. Pharmacokinetics/pharmacodynamics ii. Drug interactions iii. Age, gender, and ethnicity issues iv. Genomics III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
IX. Sleep Studies X. Neurophysiologic testing XI. Other E. Treatment I. General treatment planning and decision making II. General principles of psychopharmacology and neuropharmacology i. Pharmacokinetics/pharmacodynamics ii. Drug interactions iii. Age, gender, and ethnicity issues iv. Genomics III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
X. Neurophysiologic testing XI. Other E. Treatment I. General treatment planning and decision making II. General principles of psychopharmacology and neuropharmacology i. Pharmacokinetics/pharmacodynamics ii. Drug interactions iii. Age, gender, and ethnicity issues iv. Genomics III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
XI. Other E. Treatment I. General treatment planning and decision making II. General principles of psychopharmacology and neuropharmacology i. Pharmacokinetics/pharmacodynamics ii. Drug interactions iii. Age, gender, and ethnicity issues iv. Genomics III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
E. Treatment I. General treatment planning and decision making II. General principles of psychopharmacology and neuropharmacology i. Pharmacokinetics/pharmacodynamics ii. Drug interactions iii. Age, gender, and ethnicity issues iv. Genomics III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
I. General treatment planning and decision making II. General principles of psychopharmacology and neuropharmacology i. Pharmacokinetics/pharmacodynamics ii. Drug interactions iii. Age, gender, and ethnicity issues iv. Genomics III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
II. General principles of psychopharmacology and neuropharmacology i. Pharmacokinetics/pharmacodynamics ii. Drug interactions iii. Age, gender, and ethnicity issues iv. Genomics III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
i. Pharmacokinetics/pharmacodynamics ii. Drug interactions iii. Age, gender, and ethnicity issues iv. Genomics III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
ii. Drug interactions iii. Age, gender, and ethnicity issues iv. Genomics III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
iii. Age, gender, and ethnicity issues iv. Genomics III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iiii. Selective serotonin reuptake inhibitors (SSRI)	
iv. Genomics III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
III. Specific pharmacologic agents i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
i. Tricyclics and heterocyclics ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
ii. Monoamine oxidase inhibitors iii. Selective serotonin reuptake inhibitors (SSRI)	
iii. Selective serotonin reuptake inhibitors (SSRI)	
iv. Selective norepinephrine reuptake inhibitors (NRI)	
v. Selective serotonin-norepinephrine reuptake inhibitors (SNRI)	
vi. Other antidepressants	
vii. Lithium	
viii. Anticonvulsants	
ix. Benzodiazepines	
x. Beta blockers	
xi. Alpha agonists	
xii. Typical antipsychotics	
xiii. Atypical antipsychotics	
xiv. Psychostimulants	
xv. Hypnotics and sedatives	
xvi. Cognitive enhancers	
xvii. Calcium channel blockers	
xviii. Dopamine agonists (including L-DOPA)	
xix. Anticholinergics	
xx. Opioid agonists/antagonists	



xxi. Other agents used in the management of psychiatric disorders
xxii. Other agents used in the management of neurologic disorders
xxiii. Other agents used in the management of other medical disorders
IV. Treatment of substance-related and addictive disorders
i. Pharmacologic
a. Management of intoxication and withdrawal
b. Management of use and relapse prevention
c. Management of co-occurring conditions
ii. Nonpharmacologic
a. Management of intoxication and withdrawal
b. Management of use and relapse prevention
c. Management of co-occurring conditions
V. Treatment of aggression/self-injury
i. Pharmacologic
ii. Nonpharmacologic
VI. Treatment of sleep-wake disorders
i. Pharmacologic
ii. Nonpharmacologic
VII. Treatment of pain
i. Pharmacologic
ii. Nonpharmacologic
VIII. Treatment of neuroleptic malignant syndrome, TDEPS, and serotonin syndrome
i. Pharmacologic
ii. Nonpharmacologic
IX. Treatment in special situations
i. Renal disease
ii. Hepatic disease
X. Augmentation strategies
XI. Nonpharmacologic somatic treatment
i. Biofeedback
ii. Electroconvulsive therapy
iii. Phototherapy
iv. Chronotherapy
v. Vagal nerve stimulation
vi. rTMS (repetitive transcranial magnetic stimulation)
vii. Neurosurgical approaches
· · · · · · · · · · · · · · · · · · ·



	viii. Other
	XII. Psychotherapy
	i. Supportive
	ii. Cognitive and/or behavioral (including DBT)
	iii. Interpersonal
	iv. Psychodynamic and psychoanalytic
	v. Couples and family
	vi. Group
	vii. Crisis intervention (e.g. critical incident debriefing, psychological debriefing/early
	intervention)
	viii. Motivational interviewing
	ix. Other (e.g., hypnotherapy, sex therapy, mindfulness, meditation)
	XIII. Psychosocial interventions
	i. Psychoeducation
	ii. Vocational and occupational rehabilitation
	iii. Self-help groups (e.g., AA, NA)
	iv. Community-based treatment programs (e.g., halfway houses, day hospitals,
	multimodal treatment programs, therapeutic communities, opioid agonist treatment
	programs)
	v. Other
F.	Interpersonal and communication skills
	I. Communication with patients
	II. Communication with other professionals
	III. Communication with the public
	IV. Communication with patients' families
	V. Communication with the healthcare team
G.	Professionalism, ethics, and the law
	I. Sensitivity to diversity
	II. Adherence to ethical principles (e.g., informed consent, research issues, clinical care)
	III. Fatigue management, work-life balance, and physician well-being
	IV. Professional behavior
	V. Participation in the professional community
	VI. Legal issues in psychiatry
	VII. End of life issues
Н.	· ·
	I. Development and execution of lifelong learning



A Member Board of the American Board of Medical Specialties (ABMS)

		i.	Self-assessment and self-improvement	
		ii.	Use of evidence in the clinical workflow	
	II.	For	mal practice-based quality improvement	
I.	Systems-based practice			
	l.	I. Patient safety and the healthcare team		
		i.	Medical errors, patient safety, quality improvement, and improvement activities	
		ii.	Regulatory and educational activities related to patient safety	
	II. Resource management			
		i.	Parity	
		ii.	Access to care	
		iii.	Telepsychiatry	
	III. Community-based care			
		i.	Community based programs	
			a. Other (e.g. nursing homes, skilled nursing facilities, assisted living)	
		ii.	Prevention	
		iii.	Recovery and rehabilitation	
		iv.	Integrated care (collaborative care)	
	IV.		sultation to nonpsychiatric medical providers and nonmedical systems (e.g., military,	
			pols, businesses, forensic)	
	V.		lic health and prevention, and public policy	
	VI.	Doc	umentation of practice, management of records, insurance, and reimbursement	